BIO-KOREA
26.5.2021 15:02:11 CEST | Business Wire | Press release
As one of the most important global bio-health conventions, BIO KOREA 2021 International Convention has garnered great attention from home and abroad. To facilitate the discussion on the future bio-health industry in the ‘COVID-19 era’, the BIO KOREA 2021 to be held on June 9 to 21 will evolve around the theme of “New Normal: Breaking Barriers with Bio Innovation”.
BIO KOREA organizing committee announced the main programs, deep-diving into business strategies in the post-pandemic era.
The Four Programs Focusing on Biohealth Industry and Business
BIO KOREA 2021 Business Forum will focus on a virtual partnering system allowing attendees to schedule virtual meetings to maximize their business development and licensing potential.
International participation continues to grow. Numerous companies from 20+ countries already joined and are expected to showcase their advanced technologies at BIO KOREA 2021.
As an event involving various kinds of discussion, BIO KOREA attracts not only leading biohealth companies in Korea such as SK Chemicals, Chong Kun Dang, ShinPoong Pharm, Kolon Life Science, etc, but also promising SMEs like PharmCADD, WELT, Oncocross, Biot Korea, all of which are eager to grow their business. 24-hour meeting slots will strengthen your digital network across time zones. Also, company presentations will be livestreamed on the official BIO KOREA platform.
The Exhibition will be held both online and on-site, as a hybrid format, which will showcase the cutting-edge technologies and products of exhibitors in various ways. 300+ exhibitors, from start-up to global enterprise, will be at BIO KOREA’s exhibition. Participants can meet on-site exhibitors through live streaming on the online platform during the event.
There will be a Digital Healthcare-themed pavilion introducing the industrial rookies of Digital Wellness, Mobile Healthcare, Digital Therapeutics, Big Data, and AI, etc. Also, COVID-19 show room will show participants how biohealth serves as a cure for the pandemic.
The Conference of BIO KOREA will consist of valuable expert-level lectures regarding the most pressing industry topics including Digital Health, Drug Development, and Post COVID-19. BIO KOREA 2021 conference covering 18 topics with 170+ speakers, will bring the most up-to-date conversations of biohealth both online and on-site.
Invest Fair is an event where pharmaceuticals, bio, and healthcare companies that are advancing into the global market and developing new drugs introduce their leading technology, vision and strategy to the investors. Along with online hosting, it maintains the participants’ attendance with impressive lineups of 19 companies such as Lunit, Tium BIO, VaxcellBio and Genesystem.
BIO KOREA 2021 will be available both Online and On-site
BIO KOREA presents invaluable information on the industry’s trends around the world. This year, the global audience will have a front-row seat to discover and see the latest technology. All BIO KOREA programs will be livestreamed from June 9 to June 21. The program at a glance is on https://www.biokorea.org/program/schedule.asp .
For more updates: https://www.biokorea.org
About BIO KOREA
BIO KOREA serves as a venue place for practical business correspondence as well as international information and technology exchange, invigorating the bio industry. For 15 years, BIO KOREA has been a place of bringing together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs. It has been providing abundant opportunities to enhance competitive edges within the convergence industry centered around biotechnology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005412/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom